高危左心室肥厚患者心肌僵硬度增加:射血分数保留心衰B期的标志
结果显示LVH组左室心肌僵硬度常数较对照组高约30%(0.053±0.027 vs 0.042±0.020,P=0.028),提示该高僵硬状态可能是从健康心脏向射血分数保留心衰(HFpEF)过渡的标志。
要点
- LVH伴心脏生物标志物升高患者左室心肌僵硬度较健康对照增加约30%。
- 该人群左室在相同充盈压力下容积更小,提示舒张功能受损。
- 心肌僵硬度增加可能是HFpEF B期的病理生理标志。
核心结论
- LVH伴生物标志物升高(HFpEF B期)患者左室心肌僵硬度高于年龄性别匹配对照,可能代表向HFpEF过渡的状态。
研究设计与样本
- 采用右心导管和三维超声,通过下体负压和快速盐水输注调节前负荷以定义左室压力-容积关系。
主要发现
- 两组间体型、血压和基线肺毛细血管楔压存在显著差异(如肺毛细血管楔压:LVH组13.4±2.7 vs 对照组11.7±1.7 mm Hg,P<0.0001)。
- LVH组左室扩张性低于对照(相同充盈压力下容积更小)。
- 以跨壁充盈压力(肺毛细血管楔压-右房压)表达前负荷时,LVH组左室心肌僵硬度常数较对照组高近30%(0.053±0.027 vs 0.042±0.020,P=0.028)。
临床怎么用
- 对于LVH伴心脏生物标志物升高的患者,应关注左室心肌僵硬度增加这一HFpEF B期标志。
- 该发现提示此类高危人群可能需要早期干预,但改善左室顺应性的干预(如运动训练)能否预防HFpEF尚需进一步研究。
局限性
- 研究为观察性设计,样本量有限,无法确定因果关系。
- 需进一步研究明确改善左室顺应性的干预是否可预防高危个体发展为HFpEF。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with left ventricular hypertrophy (LVH) and elevated cardiac biomarkers in middle age are at high risk for the development of heart failure with preserved ejection fraction (HFpEF). However, it is unknown what the pathophysiological underpinnings of this high-risk state may be. We tested the hypothesis that patients with LVH and elevated cardiac biomarkers would demonstrate elevated left ventricular (LV) myocardial stiffness in comparison with healthy controls as a key marker for future HFpEF. METHODS: Forty-six patients with LVH (LV septum >11 mm) and elevated cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [>40 pg/mL] or troponin T [>0.6 pg/mL]) were recruited, along with 61 age- and sex-matched (by cohort) healthy controls. To define LV pressure-volume relationships, right heart catheterization and 3-dimensional echocardiography were performed while preload was manipulated using lower body negative pressure and rapid saline infusion. RESULTS: There were significant differences in body size, blood pressure, and baseline pulmonary capillary wedge pressure between groups (eg, pulmonary capillary wedge pressure: LVH, 13.4±2.7 versus control, 11.7±1.7 mm Hg, P<0.0001). The LV was less distensible in LVH than in controls (smaller volume for the same filling pressure). When preload was expressed as transmural filling pressure (pulmonary capillary wedge pressure - right atrial pressure), LV myocardial stiffness was nearly 30% greater in LVH than in controls (LVH stiffness constant, 0.053±0.027 versus controls, 0.042±0.020, P=0.028). CONCLUSIONS: LV myocardial stiffness in patients with LVH and elevated biomarkers (stage-B HFpEF) is greater than in age- and sex-matched controls and thus appears to represent a transitional state from a normal healthy heart to HFpEF. Although the LV myocardial stiffness of patients with LVH is greater than that of healthy controls at this early stage, further studies are required to clarify whether interventions such as exercise training to improve LV compliance may prevent the full manifestation of the HFpEF syndrome in these high-risk individuals. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT03476785 and NCT02039154.
引用
- Hieda M, Sarma S, Hearon CM, et al. Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction. Circulation. 2019. PMID: 31865771. doi:10.1161/CIRCULATIONAHA.119.040332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。